Purchase this article with an account.
Pankaj Singh, Svenja Deuchler, Michael Mueller, Thomas Kohnen, Diego Sousa-Martins, Beatriz Pinheiro-Torres, Frank H J Koch; Chromovitrectomy with Vitreodyne™.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4452.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To test the efficacy, advantages, and safety of a crystalline lutein-based dye called Vitreodyne™ for improving identification and removal of the vitreous, posterior hyaloid and peripheral vitreous base during chromovitrectomy in a observational, non-randomized, open case series.
Eighteen patients with the diagnosis of epiretinal membranes (ERM), macular holes (MH), diabetic retinopathies (DRP), vitreomacular traction syndroms (VMTS) and retinal detachments (RD), plus indication for pars plana vitrectomy (PPV) were invited to participate in this study. All patients were operated with a standard technique including Vitreodyne™ – a dye composed of crystalline lutein. Surgical technology included a standard vitrectomy with detachment of a preoperatively attached posterior vitreous base. Any further steps were performed according to the clinical standards. At the end of the procedure the surgeon had to answer a questionnaire in order to evaluate the efficacy of Vitreodyne™. Before and after surgery, patients underwent the routine standard ophthalmology examinations during a mean follow-up of 3 months.
Vitreodyne™ showed to be useful for vitreous and posterior hyaloid removal and moreover, to be superior to existing alternative dyes. The use of this dye also results in a faster and more prominent visualization, measured by the lowered risk of iatrogenic damage of the retina during pars plana vitrectomy and/or ERM peeling. The orange color of the crystalline lutein was considered adequate in 100% of the cases. The vitreous and posterior hyaloid visualization was considered good in 89,5% and 83,3% respectively. Additionally, Vitreodyne™ demonstrated to be useful to stain the vitreous base in cases where the structures were very thin due to myopia. No dye-related adverse events were observed after a mean follow-up of 3 months. The intraocular pressure (IOP) did not suffer changes during the follow-up and the best-corrected visual acuity (BCVA) improved in all cases.
This study showed that the approved Vitreodyne™ comprised of lutein/zeaxanthin crystals was very useful for chromovitrectomy. The main advantage of this dye was the ability to improve the intraoperative identification of the posterior hyaloid/vitreous base and to detect even the smallest vitreous residuals on the retinal surface. Moreover, Vitreodyne™ showed no dye-adverse event during the mean follow-up period.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only